<DOC>
	<DOC>NCT00316732</DOC>
	<brief_summary>This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.</brief_summary>
	<brief_title>Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia). Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH. Patients must only enter the study after the decision to prescribe dutasteride has been undertaken. Exclusion criteria: None specified</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Avodart</keyword>
	<keyword>IPSS</keyword>
	<keyword>BPH</keyword>
	<keyword>dutasteride</keyword>
	<keyword>EQ-5D</keyword>
	<keyword>Observational</keyword>
</DOC>